These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18775810)

  • 1. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.
    Gozgit JM; Bebernitz G; Patil P; Ye M; Parmentier J; Wu J; Su N; Wang T; Ioannidis S; Davies A; Huszar D; Zinda M
    J Biol Chem; 2008 Nov; 283(47):32334-43. PubMed ID: 18775810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
    Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
    Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
    Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
    Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
    BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells.
    Kumar JK; Ping RY; Teong HF; Goh S; Clément MV
    Int J Biochem Cell Biol; 2011 Apr; 43(4):594-603. PubMed ID: 21187157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.
    Tognon R; Gasparotto EP; Neves RP; Nunes NS; Ferreira AF; Palma PV; Kashima S; Covas DT; Santana M; Souto EX; Zanichelli MA; Simões BP; de Souza AM; Castro FA
    J Hematol Oncol; 2012 Feb; 5():2. PubMed ID: 22300941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
    Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
    Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
    Ahmed KB; Warner SL; Chen A; Gourley ES; Liu X; Vankayalapati H; Nussenzveig R; Prchal JT; Bearss DJ; Parker CJ
    Exp Hematol; 2011 Jan; 39(1):14-25. PubMed ID: 20934482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
    Zhang T; Jiang B; Zou ST; Liu F; Hua D
    World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
    Waibel M; Solomon VS; Knight DA; Ralli RA; Kim SK; Banks KM; Vidacs E; Virely C; Sia KC; Bracken LS; Collins-Underwood R; Drenberg C; Ramsey LB; Meyer SC; Takiguchi M; Dickins RA; Levine R; Ghysdael J; Dawson MA; Lock RB; Mullighan CG; Johnstone RW
    Cell Rep; 2013 Nov; 5(4):1047-59. PubMed ID: 24268771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation.
    Fujinaka Y; Takane K; Yamashita H; Vasavada RC
    J Biol Chem; 2007 Oct; 282(42):30707-17. PubMed ID: 17728251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.
    Baffert F; Régnier CH; De Pover A; Pissot-Soldermann C; Tavares GA; Blasco F; Brueggen J; Chène P; Drueckes P; Erdmann D; Furet P; Gerspacher M; Lang M; Ledieu D; Nolan L; Ruetz S; Trappe J; Vangrevelinghe E; Wartmann M; Wyder L; Hofmann F; Radimerski T
    Mol Cancer Ther; 2010 Jul; 9(7):1945-55. PubMed ID: 20587663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
    Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
    Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2/STAT5/Bcl-xL signalling is essential for erythropoietin-mediated protection against apoptosis induced in PC12 cells by the amyloid β-peptide Aβ25-35.
    Ma R; Hu J; Huang C; Wang M; Xiang J; Li G
    Br J Pharmacol; 2014 Jul; 171(13):3234-45. PubMed ID: 24597613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of
    Gao X; Chu LJ; Yan ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun; 32(3):663-669. PubMed ID: 38926951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant inactivation of the epidermal growth factor receptor, phosphatidylinositol 3-kinase/Akt and Janus tyrosine kinase 2/signal transducer and activator of transcription 3 signalling pathways in cardiotoxin III-treated A549 cells.
    Su JC; Lin KL; Chien CM; Chuang PW; Chang LS; Lin SR
    Clin Exp Pharmacol Physiol; 2010 Aug; 37(8):833-40. PubMed ID: 20456425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.